{"id":"vaxigrip-tetra-sanofi-pasteur-europe","safety":{"commonSideEffects":[{"rate":"10–40%","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15%","effect":"Myalgia (muscle pain)"},{"rate":"5–15%","effect":"Headache"},{"rate":"5–10%","effect":"Fatigue"},{"rate":"<5%","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL3923877","moleculeType":"Small molecule","molecularWeight":"406.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles representing four circulating influenza strains (two A subtypes and two B lineages). Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and T-cell immunity that protect against infection with matching influenza viruses.","oneSentence":"Vaxigrip Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:56.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT06336317","phase":"PHASE4","title":"Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-24","conditions":"Acute Myocardial Infarction, Cardiovascular Diseases, Inflammatory Response","enrollment":90},{"nctId":"NCT05585983","phase":"PHASE4","title":"INfluenza VaccInation To Mitigate typE 1 Diabetes","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-12-14","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05129436","phase":"","title":"Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2020-10-10","conditions":"Seasonal Influenza Vaccination","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vaxigrip Tetra Sanofi Pasteur Europe","genericName":"Vaxigrip Tetra Sanofi Pasteur Europe","companyName":"Aarhus University Hospital","companyId":"aarhus-university-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Vaxigrip Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}